文献速递抗栓抗凝管理药物不良反应与药物警戒

抗Xa因子活性检测指导急诊口服Xa抑制剂逆转治疗的应用

Utilization of anti-factor Xa levels to guide reversal of oral factor Xa inhibitors in the emergency department.
PubMed 文献 · Am J Health Syst Pharm · 2022-01-01

本研究回顾性分析2019年6月至2020年4月急诊科获取的30例抗Xa因子活性检测,评估其在口服Xa抑制剂相关急性出血或需紧急操作患者中的作用。结果显示抗Xa检测中位报告时间45.9分钟,37%患者根据检测结果接受逆转治疗,抗Xa水平低于30 ng/mL者均未接受凝血酶原复合物类逆转剂。检测可用于排除口服Xa抑制剂存在,避免不必要的逆转剂给药。

要点

  • 抗Xa检测中位报告时间45.9分钟,可快速辅助急诊决策。
  • 抗Xa水平低于30 ng/mL者均未接受aPCC或PCC逆转治疗。
  • 抗Xa检测可用于排除口服Xa抑制剂存在,避免不必要的逆转剂给药。

核心结论

  • 抗Xa因子活性检测在急诊管理需紧急逆转的口服Xa抑制剂患者中具有新作用。
  • 该检测可用于排除口服Xa抑制剂存在,避免不必要的抗凝逆转剂给药。

研究设计与样本

  • 回顾性研究,分析2019年6月1日至2020年4月30日急诊科获取的抗Xa因子活性检测。
  • 最终纳入30例抗Xa因子活性检测进行分析。

主要发现

  • 从样本采集到抗Xa检测结果的中位时间为45.9分钟(四分位距35.3-54.7分钟)。
  • 抗凝逆转剂包括活化凝血酶原复合物浓缩物(aPCC)或凝血酶原复合物浓缩物(PCC)。
  • 2例患者在到达急诊科前已接受PCC,仍采集了抗Xa水平。
  • 抗Xa水平低于30 ng/mL的患者中,无人在抗Xa水平测定后接受aPCC或PCC。

关键数值与推荐

  • 抗Xa水平低于30 ng/mL的患者均未接受aPCC或PCC逆转治疗。

临床怎么用

  • 急诊面对口服Xa抑制剂相关急性出血或需紧急操作时,可考虑检测抗Xa因子活性辅助决策。
  • 抗Xa水平低于30 ng/mL可用于排除口服Xa抑制剂存在,避免不必要的逆转剂给药。

局限性

  • 回顾性研究,样本量仅30例抗Xa检测,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Oral factor Xa inhibitors (FXaIs) are increasingly utilized for outpatient anticoagulation therapy; however, laboratory monitoring is not routinely used to assess the safety and efficacy of these agents. We aimed to evaluate the role of chromogenic anti-factor Xa (anti-Xa) assays in the emergency department (ED) in the setting of patients with an acute bleed or requiring emergent procedures. METHODS: A retrospective review of anti-Xa levels obtained in the ED between June 1, 2019, and April 30, 2020, was completed. Data were collected to describe the clinical setting of anti-Xa level collection, oral FXaIs used before admission, administration of reversal agents, and patient disposition to further characterize the role of anti-Xa levels in the management of rivaroxaban and apixaban reversal. RESULTS: Thirty anti-Xa levels were included in the final analysis. The median time from sample collection to anti-Xa assay result was 45.9 minutes (interquartile range, 35.3-54.7 minutes). Eleven patients (37%) received anticoagulation reversal after their anti-Xa levels were determined. Anticoagulation reversal agents included either activated prothrombin complex concentrates (aPCCs) or prothrombin complex concentrates (PCCs). Anti-Xa levels were collected in 2 patients who had received PCCs before arrival at our ED. Of the patients with anti-Xa levels below 30 ng/mL, none received aPCCs or PCCs after their anti-Xa levels were determined. Anti-Xa assays were used to rule out the presence of FXaIs in 3 patients. CONCLUSION: This study illustrates the novel role of anti-Xa levels in managing patients with an emergent need for reversal in the ED. The assay may be used to rule out the presence of oral FXaIs and avoid unnecessary administrations of anticoagulation reversal agents.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Zepeski AE, Faine BA, Merrill AE, et al. Utilization of anti-factor Xa levels to guide reversal of oral factor Xa inhibitors in the emergency department. Am J Health Syst Pharm. 2022. PMID: 34363457. doi:10.1093/ajhp/zxab326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。